Trials / No Longer Available
No Longer AvailableNCT01798914
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Mannkind Corporation · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to allow patients with specific needs for inhaled insulin to continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn from the market.
Detailed description
A Phase 3, open label, multicenter, safety follow up trial to convert the treatment of subjects currently using Exubera to treatment with TI Inhalation Powder
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Technosphere Insulin Inhalation Powder | Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2015-04-01
- Completion
- 2015-05-01
- First posted
- 2013-02-26
- Last updated
- 2016-01-20
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01798914. Inclusion in this directory is not an endorsement.